Viatris Inc
Change company Symbol lookup
Select an option...
VTRS Viatris Inc
MSEX Middlesex Water Co
EQIX Equinix Inc
PEAK Healthpeak Properties Inc
TAL TAL Education Group
CPLP Capital Product Partners LP
ONFO Onfolio Holdings Inc
CALB California BanCorp
LI Li Auto Inc
TASK Taskus Inc
Go

Health Care : Pharmaceuticals | Mid Cap Value
Company profile

Viatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as its anti-retroviral franchise. Its portfolio comprises approximately 1,400 approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. It operates approximately 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.

Closing Price
$9.21
Day's Change
0.49 (5.62%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.21
Day's Low
8.79
Volume
(Below Average)
Volume:
8,796,084

10-day average volume:
10,546,291
8,796,084

VTRS's position in the Pharmaceuticals industry

Industry PeersVTRSZTSCTLTSAVAAMPH

Summary

Company ProfileViatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily...
Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices...
Go to ZTS summary
Catalent, Inc. is a provider of development and manufacturing solutions for drug, cell and gene therapies biologics, vaccines, and consumer health products. The Company’s segments include Biologics...
Go to CTLT summary
Cassava Sciences, Inc. is a clinical-stage biotechnology company. The Company is primarily focused on developing the drug for the treatment of neurodegenerative diseases, such as Alzheimer's disease...
Go to SAVA summary
Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company. The Company is primarily focused on developing, manufacturing, marketing and selling generic and injectable, inhalation, and...
Go to AMPH summary
52-Week Change

VS. INDUSTRY
-31.42%
-20.10%
-38.16%
-23.18%
49.42%
Market Cap

VS. INDUSTRY
$10.3B
$69.6B
$13.4B
$1.8B
$1.4B
Beta

VS. INDUSTRY
1.2
0.8
1.4
0.2
0.7
Dividend Yield

VS. INDUSTRY
5.63%
0.87%
--
--
--
P/E (TTM, GAAP)

VS. INDUSTRY
13.63x
33.72x
26.44x
--
15.88x
Data as of

Fundamentals

Total Revenue (TTM)

VS. INDUSTRY
$17.2B
$8.0B
$4.8B
$0.0
$476.9M
Profit Margin

VS. INDUSTRY
4.43%
26.12%
10.75%
--
19.60%
Earnings Growth
(5 year, GAAP)

VS. INDUSTRY
--
20.99%
26.67%
--
43.27%
Revenue Growth (TTM)

VS. INDUSTRY
10.15%
7.87%
20.76%
--
24.19%
Data as of
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.